TNFα inhibitors—The most well-known TNFα inhibitors are infliximab and adalimumab, monoclonal antibodies developed in the last decades to cope with chronic inflammatory disorders such as RA, IBD, psoriasis, psoriatic arthritis [176]. The gene discussed is TNF; the disease is inflammatory bowel disease.